<?xml version="1.0" encoding="UTF-8"?>
<ref id="B19-molecules-22-01290" class="ref">
 <label class="label">19.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Uehleke</surname>
    <given-names class="given-names">B.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Schaper</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Dienel</surname>
    <given-names class="given-names">A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Schlaefke</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Stange</surname>
    <given-names class="given-names">R.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder</article-title>
  <source class="source">Phytomedicine</source>
  <year class="year">2012</year>
  <volume class="volume">19</volume>
  <fpage class="fpage">665</fpage>
  <lpage class="lpage">671</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1016/j.phymed.2012.02.020</pub-id>
  <?supplied-pmid 22475718?>
  <pub-id pub-id-type="pmid" class="pub-id">22475718</pub-id>
 </element-citation>
</ref>
